Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1

Yong Gao, Chanuka Wijewardhana, Jamie F S Mann

Research output: Contribution to journalReview article (Academic Journal)peer-review

56 Citations (Scopus)


It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a central theme and has ultimately led to a significant roadblock in HIV vaccine development. Consequently, significant efforts have been applied to generate novel vaccine antigens and delivery agents, which mimic viral structures for optimal immune induction. Here, we review the latest developments that have occurred in the nanoparticle vaccine field, with special emphasis on strategies that are being utilized to attain highly immunogenic, systemic, and mucosal anti-HIV humoral and cellular immune responses. This includes the design of novel immunogens, the central role of antigen-presenting cells, delivery routes, and biodistribution of nanoparticles to lymph nodes. In particular, we will focus on virus-like-particle formulations and their preclinical uses within the HIV prophylactic vaccine setting.

Original languageEnglish
Pages (from-to)345
JournalFrontiers in Immunology
Publication statusPublished - 2018


  • AIDS Vaccines/immunology
  • Acquired Immunodeficiency Syndrome/immunology
  • Animals
  • HIV-1/immunology
  • Humans
  • Immunity, Cellular/drug effects
  • Immunity, Humoral/drug effects
  • Liposomes
  • Nanoparticles/therapeutic use
  • Vaccines, Virus-Like Particle/immunology


Dive into the research topics of 'Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1'. Together they form a unique fingerprint.

Cite this